Fusen Pharmaceutical Company Limited (HKG:1652)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Shuanghuanglian Oral Solutions and Shuanghuanglian Injections	273.37M	326.03M	565.61M	491.76M	385.66M
Shuanghuanglian Oral Solutions and Shuanghuanglian Injections Growth	-16.15%	-42.36%	15.02%	27.51%	-20.78%
Total	273.37M	326.03M	565.61M	491.76M	385.66M
Total Growth	-16.15%	-42.36%	15.02%	27.51%	-20.78%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
People's Republic of China (PRC)	273.37M	326.03M	565.61M	491.76M	385.66M
People's Republic of China (PRC) Growth	-16.15%	-42.36%	15.02%	27.51%	-20.78%
Total	273.37M	326.03M	565.61M	491.76M	385.66M
Total Growth	-16.15%	-42.36%	15.02%	27.51%	-20.78%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 18, 2026

Data Sources Report a data error